NCT02839460已完成不适用
A Single-Center, Prospective Study to Evaluate Biomarkers of Skeletal Muscle Atrophy in Sarcopenia
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Serum concentration of TWEAK at day 1
研究概览
简要总结
This is a single center, prospective biomarker study to evaluate serum levels of TWEAK and expression levels of TWEAK and Fn14 in muscle biopsies from patients with sarcopenia as well as healthy, physically active controls.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 65 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •To be eligible to participate in this study, all candidates must meet the following eligibility criteria at Baseline or at the time point specified in the individual eligibility criterion listed:
- •All Participants
- •Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information in accordance with national and local subject privacy regulations
- •Subjects with Sarcopenia
- •Men and postmenopausal women of 65 years of age or older
- •Gait speed measured over 4 meters of <1.0 m/s OR grip strength < 26 kg for men or < 16 kg for women.
- •Appendicular skeletal muscle adjusted for BMI by DXA ≤ 0.789 for men and ≤ 0.512 for women.
- •Weigh at least 40kg;
- •Self-reported difficulty climbing 10 steps OR walking outside on level ground for 1/4 mile
- •Healthy Controls
- •Men and postmenopausal women of 65 Years of age or older
- •Body mass index (BMI) between 18.5 and 30 kg/m2 inclusive at the time of Screening
- •Measures of Physical Performance and Lean Mass exceed thresholds defined for Sarcopenia group.
- •≥ 150 minutes/week moderate-intensity physical activity OR regular engagement in resistance training ≥ 2 days/week
- •Willing to maintain a consistent diet and pattern of physical activity for the duration of the study
排除标准
- •Candidates will be excluded from study entry if any of the following exclusion criteria exist at Screening:
- •History of human immunodeficiency virus (HIV), hepatitis B or C, or tuberculosis (TB)
- •Immunocompromized subjects, as determined by the Investigator, based on medical history, physical examination, or laboratory testing, or due to prior or current immunosuppressive or immunomodulating treatment, including, but not limited to, HIV infection, history of organ transplantation, and anti-rejection therapy
- •Acute infection (urinary, respiratory, other) within past week or hospitalization within one month
- •Participation in any interventional clinical study within 12 weeks
- •A lower limb fracture in the past 6 months or any impairment or disease severely affecting gait (e.g. stroke with hemiparesis, myasthenia gravis, Parkinson's disease, peripheral polyneuropathy, intermittent claudication in advanced peripheral vascular disease, spinal stenosis, or severe osteoarthritis of the knee or hip);
- •Any underlying muscle disease including active myopathy or muscular dystrophy.
- •Confirmed diagnosis of heart failure classified as New York Heart Association Class III and IV (e.g. cardiomyopathy) or hypertrophic cardiomyopathy.
- •Type I diabetes or uncontrolled Type 2 diabetes (HA1C ≥ 9).
- •Requires regular assistance from another person for general activities of daily living (e.g. bathing, dressing)
- •Moderate to Vigorous Exercise performed in week prior to study visits (temporary exclusion - will be rescheduled)
- •Any other condition judged by the Principal Investigator or Study Physician to preclude safe participation in the study
结局指标
主要结局
Serum concentration of TWEAK at day 1
时间窗: Day 1
次要结局
- Relative expression levels of TWEAK mRNA in muscle biopsy at day 1(Day 1)
- Relative expression levels of Fn14 mRNA in muscle biopsy at day 1(Day 1)
- Incidence of AEs and SAEs(Screening through Day 14)
- Correlation between serum TWEAK levels and muscle strength(Day 1)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
Safety and Performance of the da Vinci SP® Surgical System in Colorectal ProceduresColorectal NeoplasmsNCT05457244Chang Gung Memorial Hospital30
招募中
不适用
A Biomarker Exploratory Study of Dual Blockade of PD1/PDL1 and CTLA4 and Anti-angiogenic TherapyMSS Metastatic Colorectal CancersMSI Solid Tumors Refractory to PD1/PDL1 Antibody MonotherapyNCT06549907Peking University Cancer Hospital & Institute50
已完成
不适用
Correlation of Molecular Biomarkers With Biopsy Findings and Outcomes in Renal Transplant RecipientsDelayed Graft FunctionNCT02463253University of California, Davis20
已完成
1 期
The Dose Response of Prednisone on Biochemical and Clinical Makers in Adult Healthy VolunteersHealthy AdultsNCT02767089Pfizer37
已完成
4 期
Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With OcrelizumabMultiple Sclerosis, RelapsingNCT04377555Genentech, Inc.179